GuideUpdated

Peptide Regulatory News Tracker (Updated October 2026)

A reverse-chronological log of verified peptide regulatory events from 2025 to October 2026, each with a primary or credible source. Updated monthly.

October 2026 brought pressure from two new directions: Eli Lilly sued five more retatrutide sellers on October 8, bringing its total to 11 since August, and TikTok began blocking searches for peptide names on October 20. At the same time, HHS sent a policy to the White House that could widen pharmacy access to some peptides. FDA still hadn't acted on its advisory committee's July votes as of October 21, 2026. The log below lists every event we could verify, newest first.

Notice: Research peptides are sold for in-vitro laboratory research only. They are not FDA-approved, not for human or animal consumption, and this page is not medical advice.

We update this page monthly. For the analysis behind these events, see FDA peptide regulation 2026. For vendor closures in more detail, see peptide vendors that shut down.

What to watch next

  • FDA action on the PCAC votes. Adding a peptide to the 503A bulks list requires notice-and-comment rulemaking, and there's "no fixed statutory deadline," per Buchanan Ingersoll & Rooney (August 18, 2026). A September 17 Frier Levitt update said "additional FDA action is required."
  • A second PCAC meeting before the end of February 2027 on five more substances: LL-37 (cathelicidin), GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF (Restore Health Consulting).
  • More warning letters. FDA issued peptide-seller letters in March, June and August 2026.

October 2026

October 20, 2026: TikTok blocks peptide searches. Searches for BPC-157, retatrutide, semaglutide and melanotan began returning "No results found"; the general term "peptides" still worked. TikTok hadn't commented as of October 21 (EEW Magazine, citing The Verge). Details: TikTok peptide ban.

October 15, 2026: Peptide "interim access policy" sent to the White House. HHS submitted a policy for OMB review that could let pharmacies temporarily compound some popular peptides, including BPC-157, under FDA enforcement discretion. Specifics weren't published (STAT).

October 13, 2026: Two deaths reported to FDA after retatrutide products. CBS News reviewed FAERS reports of two deaths in people who took products sold as retatrutide; FDA didn't say whether it verified them. America's Poison Centers logged 862 retatrutide exposures in the three months to September (Becker's).

October 8, 2026: Eli Lilly sues five more retatrutide sellers, including online sellers American Peptides LLC, Cenexa Labs and LiveWell Peptides (Bloomberg Law). Details: Eli Lilly peptide lawsuits.

September 2026

September 25, 2026: Import Alert 66-41 republished. FDA's import alert list shows a new publish date for Import Alert 66-41, which allows detention without physical examination of unapproved new drugs promoted in the US. See peptide shipping and customs.

September 21, 2026: GLP-1 ingredient import alert revised. Import Alert 66-80, covering GLP-1 bulk drug substances, shows a September 21 revision. The alert states that of 48 GLP-1 API sites FDA evaluated, 21% were noncompliant.

September 15, 2026: Eternal Peptides ends online ordering. A September 11 report said the vendor's banner announced ordering would end September 15 at 11:59 p.m. Eastern. The report comes from another vendor's site; we couldn't view the original banner.

About September 1, 2026: August letters posted. FDA's five August 24 warning letters appeared on its public index around September 1 (JackedForums).

August 2026

August 12, 2026: Eli Lilly sues six retatrutide sellers, including online peptide sellers Astra Peptides, Legendary Peptides, Texas Peptides and Lone Star Peptide, and says it reported more than 14,000 listings to platforms (Lilly).

August 24, 2026: Five peptide sellers warned. FDA sent letters to Peptide Partners, Royal Peptides, NuScience Peptides, Peak Performance Peptides and TXP Innovations, dba Tex Peptides. The Peptide Partners letter cites health claims, a "Reconstitution Solution" and code names like "GLP-3 Reta" as evidence of human-use intent.

July 2026

July 30, 2026: Paradigm Peptides owner sentenced. Matthew Kawa received 70 months and Jennifer Stechkober 16 months after pleading guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead (US Attorney, N.D. Indiana).

July 23-24, 2026: PCAC votes on seven peptides. FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A bulks list. FDA staff recommended against all seven, per Frier Levitt. Reported votes (RAPS; Restore Health Consulting):

PeptideYesNoAbstainOutcome
BPC-157861Recommended
KPV861Recommended
TB-500861Recommended
Semax851Recommended
MOTS-c752Recommended
Epitalon741Recommended
Emideltide (DSIP)671Not recommended

The votes are non-binding and concern licensed pharmacy compounding, not research-use-only sales.

June 2026

June 17, 2026: Wholesale Peptide warned. FDA's letter to the Brooksville, FL seller cites health claims on its website.

May 26, 2026: Alabama Board of Medical Examiners notice (official notice). The board told physicians not to compound, administer or dispense "non-FDA approved or research grade peptide" to patients (McDermott Will & Schulte).

April 2026

April 30, 2026: Proposed 503B exclusion for GLP-1s. FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, with comments through June 29 (Pharmacy Times).

April 22, 2026: Category 2 page updated. FDA's Category 2 list moved BPC-157, TB-500, CJC-1295, GHK-Cu, MOTs-C and others to a table of nominations "withdrawn by the nominators." GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10 remained in Category 2.

April 15-16, 2026: FDA removes 12 peptides from Category 2 and schedules PCAC meetings. FDA announced the removal on April 15 because the nominations were withdrawn (Orrick), and published a Federal Register notice on April 16 setting the July meeting.

April 1, 2026: About 5,000 peptide parcels seized in Cincinnati. CBP officers intercepted roughly 5,000 unmanifested shipments of unapproved peptides from China, found in more than 300 master cartons (WHIO; CBP).

March 2026

March 31, 2026: Gram Peptides and others warned. Letters to Gram Peptides, Prime Sciences and other sellers, published April 7, state that "Research Use Only" labeling doesn't override website evidence of human use (ChemVerify summary).

March 6, 2026: Peptide Sciences shuts down. The vendor posted that it would "voluntarily shut down operations" (PeptideLaws.com).

February 2026

February 27, 2026: Kennedy signals Category 2 changes. HHS Secretary Robert F. Kennedy Jr. said on The Joe Rogan Experience that the administration would make peptides more accessible through lawful compounding (Orrick). Pharmacy Times reported the announcement as about 14 of 19 Category 2 peptides moving toward Category 1, and noted that this concerns compounding, not FDA approval.

February 6, 2026: FDA targets non-approved GLP-1 compounding. FDA announced it would restrict GLP-1 ingredients used in mass-marketed non-approved compounded drugs.

January 2026

January 27, 2026: Science.bio closes. Its website still shows a notice that it has decided to "permanently close and discontinue the sale of research products."

2025

December 12, 2025: Pinnacle Peptides warned (FDA).

December 2025: Ohio Board of Pharmacy guidance that "research purposes only" medications are unlawful for prescriber clinics and med spas to possess (McDermott).

September 9, 2025: GLP-1 marketers warned. Letters such as FDA's letter to GenLabMeds cite retatrutide, semaglutide and tirzepatide products.

September 8, 2025: PureRawz warned over products sold as "laboratory and research use only" (FDA).

September 5, 2025: GLP-1 "green list" import alert launched (FDA).

June 2025: Amino Asylum goes offline after a reported federal raid (PeptideLaws.com). We found no government release, so treat details as reported.

February 26, 2025: USApeptide.com warned (FDA).

How this affects the vendors we list

All eight vendors on our list were operating as of our September 26-28, 2026 checks. None received a 2025-2026 warning letter in the log above. Swiss Chems has a December 10, 2024 letter, disclosed on its review. Our order is an editors' ranking, not a sort by score (method). Terms used here are defined in the research peptide glossary.

Last updated October 21, 2026. We add events only after checking a primary or credible source. Next scheduled update: November 2026.

FAQ

Frequently asked questions

What is the latest peptide regulatory news?

As of October 21, 2026: Eli Lilly sued five more retatrutide sellers on October 8 (11 since August), HHS sent a peptide interim access policy to the White House on October 15, and TikTok began blocking searches for BPC-157, retatrutide and semaglutide on October 20. FDA still hadn't acted on the July 2026 advisory committee votes.

What did the July 2026 PCAC vote decide?

FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax for the 503A bulks list, and voted against emideltide (DSIP). The votes are non-binding and don't cover research-use-only products.

What did HHS announce about peptides in February 2026?

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. said on The Joe Rogan Experience that most peptides on FDA's Category 2 list would be reconsidered. FDA removed 12 peptides from Category 2 in April 2026 after their nominations were withdrawn.

Are research peptides legal now that some left Category 2?

Leaving Category 2 isn't approval. The Category lists govern licensed pharmacy compounding, and FDA's 2026 warning letters still treat research-use-only peptides marketed for human use as unapproved new drugs.

How often is this tracker updated?

We update it monthly and add major events, such as FDA action on the PCAC votes, when we verify them.

Related on PeptideChecked

Start hereBest peptide vendors in the USAReconstitution calculatorCOA checklistCoupon codes